Who are Imipenem/Cilastatin/Relebactam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Imipenem, Cilastatin and Relebactam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imipenem-cilastatin-relebactam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Imipenem/Cilastatin/Relebactam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imipenem/Cilastatin/Relebactam (Imipenem/Cilastatin/Relebactam) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbapenem antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Carbapenem antibiotic with beta-lactamase inhibitor Bacterial penicillin-binding proteins; serine beta-lactamases Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Imipenem/Cilastatin/Relebactam (Imipenem/Cilastatin/Relebactam) — Evopoint Biosciences Inc.. Imipenem/cilastatin/relebactam is a combination of a broad-spectrum beta-lactam antibiotic, a renal dehydropeptidase inhibitor, and a beta-lactamase inhibitor that together kill bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Imipenem/Cilastatin/Relebactam TARGET	Imipenem/Cilastatin/Relebactam	Evopoint Biosciences Inc.	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; serine beta-lactamases
Imipenem, Cilastatin and Relebactam	Imipenem, Cilastatin and Relebactam	Joseph L. Kuti, PharmD	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbapenem antibiotic with beta-lactamase inhibitor class)

Evopoint Biosciences Inc. · 1 drug in this class
Joseph L. Kuti, PharmD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imipenem/Cilastatin/Relebactam — Competitive Intelligence Brief. https://druglandscape.com/ci/imipenem-cilastatin-relebactam. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab